Clinical Trial Update: Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update describes using clinical-trials data and simulation models to estimate the cost-effectiveness of triple therapy with non-steroid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• ACE inhibitors
• Angiotensin II receptor blockers (ARB)
• Finerenone (finerenone)
• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Patients With Type 2 Diabetes | Phase 4 | Status: RECRUITING